News/ News/ R&D Rhythm doesn’t miss a beat as obesity drug clears phase 3 test Phil Taylor genetic, obesity, rare disease, Rhythm Pharma, setmelanotide 0 Comment Rhythm Pharma says it has reported positive results for its obesity drug setmelanotide in two phase 3 trials, Share X Rhythm doesn’t miss a beat as obesity drug clears phase 3 test https://pharmaphorum.com/news/rhythm-doesnt-miss-a-beat-as-obesity-drug-clears-phase-3-test/
genetic, obesity, rare disease, Rhythm Pharma, setmelanotide
0 Comment
